Rare Disease Registries Are Key to Evidence-Based Personalized Medicine: Highlighting the European Experience
Authors:
Open Access
- 4 March 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 832063
Abstract
Rare diseases, such as inherited metabolic diseases, have been identified as a health priority within the European Union more than 20 years ago and have become an integral part of EU health programs and European Reference Networks. Having the potential to pool data, to achieve sufficient sample size, to overcome the knowledge gap on rare diseases and to foster epidemiological and clinical research, patient registries are recognized as key instruments to evidence-based medicine for individuals with rare diseases. Patient registries can be used for multiple purposes, such as (1) describing the natural history and phenotypic diversity of rare diseases, (2) improving case definition and indication to treat, (3) identifying strategies for risk stratification and early prediction of disease severity (4), evaluating the impact of preventive, diagnostic, and therapeutic strategies on individual health, health economics, and the society, and (5) informing guideline development and policy makers. In contrast to clinical trials, patient registries aim to gather real-world evidence and to achieve generalizable results based on patient cohorts with a broad phenotypic spectrum. In order to develop a consistent and sustained framework for rare disease registries, uniform core principles have been formulated and have been formalized through the European Rare Disease Registration Infrastructure. Adherence to these core principles and compliance with the European general data protection regulations ensures that data collected and stored in patient registries can be exchanged and pooled in a protected environment. To illustrate the benefits and limitations of patient registries on rare disease research this review focuses on inherited metabolic diseases.Keywords
This publication has 75 references indexed in Scilit:
- Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosisNature Medicine, 2013
- Suggested guidelines for the diagnosis and management of urea cycle disordersOrphanet Journal of Rare Diseases, 2012
- Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: Focus on cerebral amino acid influxMolecular Genetics and Metabolism, 2011
- Diagnosis and management of glutaric aciduria type I – revised recommendationsJournal of Inherited Metabolic Disease, 2011
- Use of guidelines improves the neurological outcome in glutaric aciduria type IAnnals of Neurology, 2010
- Compliance to Clinical Guidelines Determines Outcome in Glutaric Aciduria Type I in the Era of Newborn ScreeningKlinische Padiatrie, 2010
- Survival after Treatment with Phenylacetate and Benzoate for Urea-Cycle DisordersNew England Journal of Medicine, 2007
- Inborn errors of metabolism: the flux from Mendelian to complex diseasesNature Reviews Genetics, 2006
- Research Network: EUROGLYCANET: a European network focused on congenital disorders of glycosylationEuropean Journal of Human Genetics, 2004
- Type I glutaric aciduria, part 1: Natural history of 77 patientsAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2003